Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-site, Prospective, Open-label Phase I-II Study on Transplantation Using Cord Blood Treated With an Optimized Dose of UM171: Optimized ECT-001-CB.

NCT07301866 is registered in ClinicalTrials.gov with Ciusss de L'Est de l'Île de Montréal as lead sponsor.

NCT NCT07301866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07301866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-site, Prospective, Open-label Phase I-II Study on Transplantation Using Cord Blood Treated With an Optimized Dose of UM171: Optimized ECT-001-CB.
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 6, 2025
Completion date
March 31, 2028
Enrollment
7 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, high risk, hematologic malignancy requiring an allogeneic hematopoietic stem cell transplant lacking a donor, myelodysplastic syndromes, high risk